Safeguarding
ORGANs.
Saving Lives.

 
080877908-laboratory-worker-examining-RET.jpg

ANGION IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY
TARGETING ACUTE AND CHRONIC ORGAN INJURY.

Our pioneering work in rational drug design optimizes the natural protective, reparative, and regenerative pathways of the body in both orphan diseases and larger clinical indications.

ANGION HAS ONGOING CLINICAL TRIALS IN TWO FORMS OF ACUTE KIDNEY INJURY:

- Phase III clinical trial for Delayed Graft Function post kidney transplantation (DGF-AKI)
- Phase II trial in Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI)

ANGION’S PRECLINICAL PIPELINE USES PRECISION MEDICINE TO TARGET:
- Chronic Organ Disease
- Fibrotic Injuries
- Inflammatory Injuries

 

ANGION PRESENTS
CORPORATE OVERVIEW AT the 8th Annual SVB Leerink Health Care Conference

 
webcast-newB.png

LATEST NEWS

01/04/2019

Angion Completes Equity Financing and Appoints Senior Executives

11/27/2018

Angion Biomedica to present at Piper Jaffray Healthcare Conference

11/12/2018

Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater Chin

34536473_xl (1).jpg

30 Million People
15% of American Adults Suffer FroM Kidney Disease

 

ANGION’S MISSION

• INCREASE AVAILABILITY OF RENAL TRANSPLANTATION

• PREVENT AND IMPROVE OUTCOME OF ACUTE KIDNEY INJURIES

• HALT PROGRESSION TO END STAGE RENAL DISEASE

29041133_xl.jpg
 



patient Advocacy

Collaborating with patients
AND THEIR FAMILIES in the fight
against kidney disease

62599761_xl.jpg